by The Preeclampsia Diagnostics Market is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preeclampsia is a pregnancy complication characterized by high blood pressure and damage to organs, primarily the liver and kidneys. The market for preeclampsia diagnostics includes various products such as blood pressure monitoring devices, proteinuria tests, and biomarker tests. Early diagnosis plays a crucial role in managing preeclampsia and avoiding complications during pregnancy. The rising maternal age and increased awareness of the importance of early diagnosis are driving the growth of this market.
Market Dynamics:
The preeclampsia diagnostics market is driven by factors such as the increasing prevalence of preeclampsia worldwide and advancements in diagnostic technologies. The growing risk factors associated with preeclampsia, such as obesity and hypertension, further contribute to market growth. Additionally, the rising focus on maternal healthcare and government initiatives to reduce maternal mortality rates fuel the demand for preeclampsia diagnostics. Furthermore, the development of novel biomarkers and non-invasive diagnostic methods offer significant opportunities for market expansion in the coming years. Overall, the Preeclampsia Diagnostics Market is expected to witness substantial growth due to the increasing awareness and focus on early diagnosis and effective management of preeclampsia.
Segment Analysis:
The Preeclampsia Diagnostics Market can be segmented based on test type, end-user, and region. The test type segment can be further divided into biomarker tests, imaging tests, and others. Among these, biomarker tests dominate the segment as they are widely used for diagnosing and monitoring preeclampsia. These tests measure the levels of specific biomarkers such as PlGF, sFlt-1, and PAPP-A in the blood or urine, which are associated with preeclampsia development. Biomarker tests are preferred due to their accuracy, non-invasiveness, and ability to detect preeclampsia at an early stage.
PEST Analysis:
Political: The political landscape plays a vital role in the growth of the Preeclampsia Diagnostics Market. Government policies and regulations regarding healthcare infrastructure, maternal health programs, and funding for research and development initiatives impact market growth.
Economic: Economic factors, such as the healthcare expenditure of a country, disposable income of individuals, and the cost of diagnostic tests, influence the adoption of preeclampsia diagnostics. Higher healthcare spending and affordability contribute to the market’s growth.
Social: Increasing awareness about the importance of prenatal care and the rising prevalence of preeclampsia among pregnant women drive the demand for diagnostics. Additionally, the growing trend of late pregnancies and lifestyle changes also contribute to the market’s expansion.
Technological: Technological advancements in diagnostic techniques, such as the development of novel biomarkers and non-invasive imaging technologies, drive market growth. These advancements enhance the accuracy, speed, and convenience of diagnosing preeclampsia.
Key Takeaways:
The global Preeclampsia Diagnostics Market Trend is expected to witness high growth, exhibiting a CAGR of 11.8% over the forecast period (2021-2028), due to increasing awareness about prenatal care and rising prevalence of preeclampsia among pregnant women. The market size for 2021 is estimated to be US$ 1,270.1 billion.
In terms of regional analysis, North America is the fastest-growing and dominating region in the Preeclampsia Diagnostics Market. The region’s growth can be attributed to the presence of advanced healthcare infrastructure, favorable reimbursement policies, and increasing government initiatives for maternal health.
Key players operating in the Preeclampsia Diagnostics Market include Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, and Miraculins Inc. These companies focus on strategic collaborations, product launches, and mergers and acquisitions to strengthen their market position and expand their product portfolio.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
